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Abstract
Background: The epidemiology of Clostridium difficile infection (CDI) has changed over the past decades with the
emergence of highly virulent strains. The role of asymptomatic C. difficile colonization as part of the clinical
spectrum of CDI is complex because many risk factors are common to both disease and asymptomatic states. In
this article, we review the role of asymptomatic C. difficile colonization in the progression to symptomatic CDI,
describe the epidemiology of asymptomatic C. difficile colonization, assess the effectiveness of screening and
intensive infection control practices for patients at risk of asymptomatic C. difficile colonization, and discuss the
implications for clinical practice.
Methods: A narrative review was performed in PubMed for articles published from January 1980 to February 2015
using search terms ‘Clostridium difficile’ and ‘colonization’ or ‘colonisation’ or ‘carriage’.
Results: There is no clear definition for asymptomatic CDI and the terms carriage and colonization are often used
interchangeably. The prevalence of asymptomatic C. difficile colonization varies depending on a number of host,
pathogen, and environmental factors; current estimates of asymptomatic colonization may be underestimated as
stool culture is not practical in a clinical setting.
Conclusions: Asymptomatic C. difficile colonization presents challenging concepts in the overall picture of this
disease and its management. Individuals who are colonized by the organism may acquire protection from
progression to disease, however they also have the potential to contribute to transmission in healthcare settings.
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Background
Clostridium difficile is a Gram-positive, spore-forming,
anaerobic bacillus that was first described in 1935 as part
of the intestinal flora of newborn infants [1]. C. difficile is
recognized as one of the most important pathogens in
hospital and community healthcare settings, with a stead-
ily rising global incidence of infection and concordant in-
crease in mortality [2, 3]. The Centers for Disease Control
and Prevention in the USA have assigned C. difficile as an
urgent threat because of its association with antibiotic use
and high mortality and morbidity [4].
The clinical spectrum of symptomatic C. difficile in-
fection (CDI) ranges from mild diarrhea to severe com-
plications such as pseudomembranous colitis, toxic
megacolon, bowel perforation, sepsis, and death [5].
Symptomatic CDI is mediated through the production of
toxins that are cytotoxic to epithelial cells of the colon,
causing extensive inflammation and epithelial tissue dam-
age to the host [6]. These toxins (toxins A and B) are im-
plicated as the major virulence factors of C. difficile. An
additional putative virulence factor, the binary toxin, is
produced by some strains, particularly the more virulent
epidemic strains such as BI/NAP1/027, and may also be
present in the absence of toxin A or toxin B [7].
Asymptomatic C. difficile colonization is the condition
where C. difficile is detected in the absence of symptoms
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of infection. It has been proposed that asymptomatic C.
difficile colonized patients may be protected from pro-
gression to infection because they can mount a humoral
immune response to clostridial toxins [8]. However,
asymptomatic C. difficile colonized patients potentially
act as an infection reservoir and may present a risk to
others [9, 10]. The number of colonized patients is
higher than symptomatic CDI cases among hospital pa-
tients, particularly when disease is endemic [11–13]. The
prevalence of asymptomatic C. difficile colonization varies
depending on a number of host, pathogen, and environ-
mental factors. These features of asymptomatic C. difficile
colonization are important to establish the contribution
that asymptomatic C. difficile colonized patients make as
potential vehicles of transmission of C. difficile in health-
care environments, particularly with the global spread of
emergent hypervirulent toxigenic strains [14].
Few studies have synthesized evidence on the role and
importance of asymptomatic C. difficile colonization in
the progression to symptomatic CDI, the transmission of
infection, or the challenges to CDI control. Therefore, we
have reviewed published literature (Additional file 1)
describing asymptomatic C. difficile colonization to better
understand the prevalence, risk factors for colonization,
mechanisms that may protect colonized patients from
progression to symptomatic CDI or recurrent disease and
the risk asymptomatic C. difficile colonized patients pose
to non-colonized patients.
Definition of symptomatic C. difficile infection and
asymptomatic C. difficile colonization
It is generally accepted that positive assays for C. difficile
toxins are indicative of active disease and that the toxins
are responsible for clinical symptoms [15, 16]. A valid-
ation study comparing reference tests for C. difficile
(toxin assay positive versus cytotoxigenic C. difficile cul-
ture positive/toxin assay negative) showed that detection
of toxins was associated with more severe CDI outcomes
[17]. However, it has also been reported that patients
with positive toxin assays can remain symptomless
[8, 10, 18]. Therefore, the sole presence of C. difficile
toxins is insufficient for a diagnosis of the disease. Conse-
quently, symptomatic CDI has been defined as:
 The presence of diarrheal symptoms (three or more
unformed stools in 24 or fewer consecutive hours)
and either
○ a stool test result positive for C. difficile toxins or
○ detection of toxigenic C. difficile, or
○ colonoscopic findings demonstrating
pseudomembranous colitis [19].
To our knowledge there is no clear definition for asymp-
tomatic CDI and the terms carriage and colonization are
often used interchangeably. Table 1 provides case defini-
tions for asymptomatic carriage and colonization identified
in this review to illustrate the heterogeneity of the defini-
tions used by different the authors and that both terms
have been used without distinction. For the sake of clarity,
while maintaining conventions of previous studies, we rec-
ommend the following definition for asymptomatic C. diffi-
cile colonization:
 The absence of diarrhea (or if present, attributable
to a cause other than CDI) without colonoscopic or
histopathologic findings consistent with
pseudomembranous colitis, and either
○ the detection of C. difficile or
○ the presence of C. difficile toxins.
Table 1 A description of different case definitions for
asymptomatic colonization and carriage with C. difficile
Term used Case definition Study reference
Colonization Patients with symptomless
colonization were defined as
symptom-free, excluding
patients recovering from
C. difficile associated diarrhea.
Shim, 1998 [8]
Asymptomatic C. difficile
colonization was defined as
a positive stool culture for
C. difficile in the absence
of diarrhea.
Loo, 2011 [13]
A case of toxigenic C. difficile
colonization was defined as
an asymptomatic individual
with tcdB gene detected in a
fecal sample by real-time PCR
Hung, 2012 [109]
Was not specifically defined
and did not distinguish between
colonization and infection. One
colonized case was symptomatic
at sampling time (personal
communication).
Arvand, 2012 [30]
Carriage Asymptomatic carriage was
defined as a positive stool
culture or cytotoxin test and
the absence of diarrhea during
hospitalization and during a
30-day period after discharge.
Kyne, 2000 [18]
Asymptomatic carriage was
considered when C. difficile or
its cytotoxin was detected in
stool from persons without
gastrointestinal symptoms.
Simor, 1993 [67]
Carriers were defined as positive
for a toxigenic C. difficile screening
test during the study period in the
absence of a clinician ordered
toxin screen determined by
electronic medical record review.
Carriers were categorized as
persistent, transient, or indeterminate.
Curry, 2013 [75]
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Novel to this definition of asymptomatic C. difficile
colonization is the acknowledgment that symptoms as-
sociated with CDI can arise from alternative underlying
conditions. Diarrhea commonly affects hospitalized pa-
tients and in the majority of the cases is attributable to
non-infectious (e.g. medication side-effects, inflamma-
tory bowel disease) and infectious causes other than CDI
[20]. The proportion of cases of nosocomial diarrhea at-
tributable to CDI may be within the range of 20 to 25 %
[21, 22]. Identification of the etiology of diarrhea (or
even to rule out C. difficile) could be challenging, par-
ticularly in critically ill patients. In cases where the
underlying cause(s) of diarrhea cannot be identified (or
CDI remains as a differential diagnosis), we suggest the
use of algorithms such as the one proposed by Polage
and colleagues [20]. They suggested that regardless of
their antibiotic exposure status, CDI should be consid-
ered in all patients with clinically significant diarrhea.
The evaluation of a patient should start by verifying the
presence of diarrhea; the frequency, consistency, volume
of stool, and duration of diarrhea should be taken into
account along with associated symptoms/signs such as
cramping, dehydration, fever, hypotension, or sepsis. If
no clear infectious cause is identified, the medical his-
tory must be reviewed for non-infectious or iatrogenic
(e.g. laxative overdose) causes.
There is no evidence that non-toxigenic C. difficile
strains can cause disease [23]. In studies reporting CDI
from patients harboring non-toxigenic strains, the cul-
tured organisms were mixed with toxigenic stains and
could not definitively be associated with disease [24, 25].
Hence, individuals with diarrhea who test positive only
for non-toxigenic strains of C. difficile should be consid-
ered asymptomatically colonized unless there is support-
ing evidence of disease, such as endoscopic findings
consistent with pseudomembranous colitis. In addition,
colonization can be transient or long term often depend-
ing on the extent and frequency of exposure to C. difficile.
Epidemiology
Prevalence estimates of asymptomatic C. difficile colonization
vary considerably between different patient groups (Table 2).
Among healthy adults with no prior risk factors for CDI,
asymptomatic C. difficile colonization prevalence varied be-
tween 0 and 15 % [15, 26–33]. The study reporting 15 %
was a prospective cohort study carried out on seven groups
of healthy individuals representing various occupations in
Japan [32]. The range of asymptomatic C. difficile
colonization prevalence among groups of study subjects
was 4 to 15 %; the groups comprised university students,
hospital workers, company employees, and defense force
personnel. Among healthy newborns and infants, the
prevalence of asymptomatic C. difficile colonization varied
between 18 and 90 % [15, 34].
Few studies have examined asymptomatic C. difficile
colonization in acute hospital care settings. In 1982, Gerd-
ing and colleagues detected 43/146 (29 %) patients colo-
nized with non-toxigenic C. difficile strains [22]. Over the
course of 10 years (1982–1991), Belmares and colleagues
reported overall colonization with non-toxigenic strains in
10 % of the patients (ranged from 5 % in 1982 to 18 % in
1984) [35]. Most studies reporting asymptomatic C. diffi-
cile colonization have targeted elderly patients in dedi-
cated long-term care facilities (LTCFs). Prevalence of
asymptomatic C. difficile colonization among elderly resi-
dents ranged from 0 to 51 %, possibly because CDI is
often endemic in units or institutions with elderly patients
[9, 30, 36, 37].
Among adults, the highest prevalence of asymptomatic
C. difficile colonization has been reported in patients with
Table 2 Prevalence of asymptomatic C. difficile colonization in different populations
Population type Range of carriage rates References
Healthy neonates and infants 18–90 % [34, 110–113]
Healthy adults – general population 0–15 % [15, 26–33]
Elderly in long-term care facilities, chronic care, or nursing homes 0–51 % [9, 30, 37, 66, 67, 70, 114–116]
Hospital Elderly 0.6–15 % [26, 68, 69, 114, 117, 118]
Inpatients (not specifically elderly) 4–29 % [10, 13, 18, 22, 73, 79, 91, 105, 106, 109, 119–121]
Rehabilitation (spinal) 11–50 % [43, 45]
HIV 4 % [122]
Healthcare workers 0–13 % [26, 32, 123]
Cystic fibrosis 18–47 % [38–41]
Hospital surgical patients on antibiotic prophylaxis 17 % [124]
Intensive care 7 % [125]
IBD (ulcerative colitis or Crohn’s disease) 11 % [95]
Hematological malignancies 8 % [94]
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cystic fibrosis (CF) and in spinal/brain injury rehabilita-
tion. Asymptomatic C. difficile colonization prevalence
ranged from 18 to 47 % in studies among CF patients,
substantially higher than other clinical subgroups (e.g. sur-
gical patients) or general hospital inpatients [38–42]. In a
case–control study, Bauer and colleagues found 26/55
(47 %) CF patients were asymptomatically colonized [38].
Yahav and colleagues reported 14 toxin-positive asymp-
tomatic C. difficile colonized patients without evidence of
diarrhea in a study of 30 CF patients compared to no
toxin-positive individuals among non-CF patients [41].
Welkon and colleagues reported asymptomatic C. difficile
colonization in 19/99 CF patients (19 %), with 12 strains
being toxigenic [40]. Another study of CF patients re-
ported asymptomatic C. difficile colonization in 12/37
(32 %) patients, rising to 43 % if patients were treated with
antibiotics [39]. The heightened vulnerability of CF pa-
tients to asymptomatic C. difficile colonization rather than
to disease has been attributed to an electrolyte transport
defect in epithelial cells that may offer protection from the
effects of clostridial toxins [41].
Rehabilitation patients also had higher asymptomatic C.
difficile colonization prevalence than other groups. In one
study, 11/22 (50 %) spinal cord rehabilitation patients
were colonized and remained asymptomatic [43]. The
asymptomatic C. difficile colonized patients in this study
also had a significantly greater length of stay (median
57 days) compared to non-colonized patients (median
6 days). Stevens and colleagues found that for 7-day incre-
ments in length of stay, the risk of healthcare-associated
CDI increased by 10 % [44]; this implies that on average,
spinal cord rehabilitation asymptomatic C. difficile colo-
nized patients will be at 52 % increased risk of developing
CDI compared to non-colonized C. difficile patients. An-
other study of asymptomatic C. difficile colonization
prevalence on admission to a rehabilitation ward reported
that 9/54 (17 %) patients without prior colonization
became colonized after admission [45]. Of these nine pa-
tients, six showed no symptoms of diarrhea. The increased
colonization rate among this group of patients is thought
to result from the rehabilitation therapy where group
activities and socialization are encouraged, facilitating
transmission.
Mechanism of colonization with C. difficile
The first stage in asymptomatic C. difficile colonization
is the ingestion of C. difficile spores [46–48]. The spores
survive the gastric acid and germinate into vegetative
cells in the anaerobic environment of the colon. C. diffi-
cile has been isolated from samples of human jejunum,
however the primary reservoir is the large intestine [49].
Vegetative C. difficile cells penetrate the mucus layer in
the large intestine using flagella and enzymatic degrad-
ation of the colonic extracellular matrix [48]. Once the
mucosal layer has been breached, in vitro assays have
demonstrated that adhesion of C. difficile cells to intes-
tinal epithelial cells is facilitated by bacterial surface
layer proteins [50].
For colonization with vegetative C. difficile cells to
occur, there must be a disruption of the normal intestinal
microbiota which usually provides colonization resistance
against C. difficile [51, 52]. The inhibitive effect of the nat-
ural gut microbiota may occur through competition for
space and nutrients or the production of compounds that
inhibit C. difficile proliferation [53]. The concept of
colonization resistance is important to understand the
mechanisms that result in the development of disease.
Therefore, there is potential to introduce non-pathogenic
organisms as probiotic agents or non-toxigenic C. difficile
strains to compete with toxigenic C. difficile strains as
novel prevention and treatment strategies [54, 55]. How-
ever, Brouwer and colleagues have challenged this concept
as they found that transconjugation of the pathogenicity
locus can occur from toxigenic to non-toxigenic C. diffi-
cile strains [56].
Toxin production and asymptomatic colonization
Secretion of toxins A and B usually occurs once C. diffi-
cile reaches the stationary phase. The first essential step
for these toxins to exert their effects is binding to recep-
tors on gut epithelial cells [6]. Disease symptoms com-
mence with toxin catalysis in the cytosol. The catalyzed
toxin products inactivate guanosine triphosphate binding
Rho proteins [6]. The subsequent depolymerization of
the actin cytoskeleton elicits a cellular response that in-
cludes neutrophil infiltration, resulting in inflammation,
and the subsequent release of cytokines and interferon
gamma [57, 58]. Cell death occurs by apoptosis following
disaggregation of the actin cytoskeleton [59]. Conse-
quently, extensive colonic inflammation and epithelial tis-
sue damage occur, leading to rapid fluid loss into the large
intestine, manifesting as acute diarrhea [6].
The role and importance of toxins A and B in progres-
sion to the disease state has been subject to debate. In
early studies using hamster models, purified toxin A was
shown to elicit symptoms consistent with disease,
whereas toxin B would only elicit a response if co-
administered with toxin A [60]. Consequently, it was sug-
gested that toxin B exerted an effect following initial tissue
damage by toxin A. The recovery of toxin A-negative,
toxin B-positive strains from symptomatic patients has
challenged the view that toxin A is the dominant virulence
factor in CDI [61, 62]. Recent work with animal models
using antibodies against toxins A and B showed that ad-
ministration of anti-toxin B antibodies either alone or in
combination with anti-toxin A was more effective at pre-
venting the development of gastrointestinal symptoms
consistent with CDI [63]. Lyras and colleagues constructed
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mutant isogenic strains of C. difficile capable of producing
either toxin A or toxin B. The toxin A producing strains
lost their pathogenicity whereas the toxin B producing
stains were as pathogenic in animal models as wild type
strains [64]. However, another group using similar gene
knockout methods to generate mutant strains pro-
duced conflicting findings with a role for both toxins A
and B [65].
Toxigenic strains of C. difficile are the most prevalent
among colonized patients; early studies cultured stool
specimens and using enzyme immunoassay (EIA) or cell
culture cytotoxicity neutralization assay reported the
proportion of toxigenic strains among asymptomatic colo-
nized patients was in excess of 50 % [31, 39, 40, 66–69].
These findings have been corroborated in later stud-
ies using real-time polymerase chain reaction (PCR)
[27, 29, 30, 32, 70]. It is important to note that both EIA
and PCR methods specifically target toxigenic C. difficile
strains and could therefore bias results reporting a higher
prevalence of these strains [71].
Duration of the colonized state
There is limited information about the duration over
which individuals remain asymptomatic after coming in
contact with C. difficile spores or the time taken to re-
vert to a non-colonized state. In a randomized placebo-
controlled trial, Johnson and colleagues compared the
efficacy of vancomycin and metronidazole for eradica-
tion of C. difficile in asymptomatic colonized patients.
Sixty, 80 and 100 % of the patients in the placebo group
were negative for C. difficile after 40, 70 and >90 days
follow-up, respectively [72]. In a prospective study,
Samore and colleagues [73] compared the incidence of
colonization in surgical, medical and intensive care
wards. Thirty two colonized patients were followed on a
weekly basis until they were discharged; 84 % of the col-
onized patients remained culture positive with median
duration of colonization of 8.5 days (range 7–29 days).
The study also showed that 3/20 (15 %) of the patients
colonized with non-toxigenic strains, none of whom de-
veloped diarrhea, were positive for toxigenic strains at
follow-up. Longer-term colonization and transmission
was investigated among 1234 healthy Japanese volun-
teers, who included university students, hospital staff,
and company employees [32]. Follow-up was performed
on 38 asymptomatic patients between 5 and 7 months
later. Of these 38 cases, C. difficile was re-isolated from
12 (32 %) individuals, half of whom yielded the same
PCR ribotypes and pulsed-field gel electrophoresis types
as previously. In a subsequent study by the same au-
thors, a 6-month follow-up of 18 colonized healthy stu-
dents found 10 (56 %) were no longer colonized and 8
(44 %) were colonized more than once, of whom 3
(38 %) harbored the same strain [27].
These findings suggest that there is marked variation
in duration of the colonized state, however the role of
repeated exposure from the environment or other colo-
nized individuals was not investigated. Limited longitu-
dinal data available about asymptomatic C. difficile
colonization warrants further epidemiological studies to
investigate the persistence of colonization and to under-
stand the role of re-exposure to the organism over time.
Transmission from colonized patients
Person-to-person transmission in hospital wards, environ-
mental contamination, and carriage of C. difficile on the
hands of healthcare workers have been described exten-
sively [74–77]. The main modes of transmission are by
the fecal-oral route and direct contact with contaminated
surfaces and fomites [78], although transmission between
healthy individuals who are asymptomatically colonized
has also been reported [32].
Spores from asymptomatically colonized patients are a
potential source of CDI and may contribute to the trans-
mission reservoir [9] and studies have clearly demonstrated
that transmission from asymptomatically colonized patients
can occur [75, 79]. Curry and colleagues investigated trans-
mission potential of asymptomatic C. difficile colonized pa-
tients using multiple-locus variable number tandem repeat
analysis. They found that 29 % of isolates from hospital-
associated CDI cases were highly related to isolates from
asymptomatic C. difficile colonized patients [75]. Clabots
and colleagues reported that patients admitted from home
without prior hospitalization in the previous month had the
lowest prevalence of asymptomatic C. difficile colonization
(6 %) but, because they represent the majority of admis-
sions, they contributed the second-highest total number of
C. difficile introductions to hospital, after patients readmit-
ted to hospital within 30 days [79]. Similarly, the length of
stay in hospital can also influence transmission. Fecal excre-
tion of C. difficile spores occurs for up to 6 weeks following
resolution of CDI symptoms [80, 81]. Furthermore, Riggs
and colleagues demonstrated that even colonized patients
who did not develop disease during a 6 months follow-up
period were shedding spores into the environment [9]. The
current CDI clinical practice guidelines from the Society of
Healthcare Epidemiologists of America (SHEA) recom-
mend maintaining contact precautions only until resolution
of diarrhea. It has been suggested that contact precautions
should be extended until time of discharge for patients
recovering from CDI. However, there is no conclusive evi-
dence to support extending contact precautions following
CDI while patients remain asymptomatic during their hos-
pital stay [81].
Asymptomatic C. difficile colonized patients in hos-
pital have the potential to contaminate the environment
and subsequently infect others [75]; however the trans-
mission potential is lower in asymptomatic C. difficile
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colonized patients than in those patients with active dis-
ease [10]. In one prospective study of acquisition rates in
an endemic CDI setting, 38/128 (29 %) environmental
samples from hospital rooms occupied by asymptomatic
C. difficile colonized patients were contaminated com-
pared to 90/128 (49 %) samples from rooms occupied by
patients with disease. This corresponds with findings
from another study of LTCF residents in which propor-
tions of positive cultures from skin sites and environmen-
tal samples were highest among residents with disease,
second highest among asymptomatic C. difficile colonized
patients and lowest among non-colonized residents [9].
Moreover, Sethi and colleagues found that even 4 weeks
after receiving therapy for CDI, the frequency of skin con-
tamination (30/52; 58 %) and environmental shedding
(26/52; 50 %) remained high in asymptomatic C. difficile
colonized patients [81]. Samore and colleagues demon-
strated that in an endemic situation carriage of C. difficile
on the hands of healthcare workers was positively corre-
lated with the extent of environmental contamination with
C. difficile [82].
The spore-forming ability of C. difficile makes it distinct
from other infectious organisms common to healthcare
settings and introduces further challenges to reduce trans-
mission. Spores can persist in the environment for long
periods and require chlorine- [83] or peroxide-based [84]
sporicidal agents or ultraviolet radiation devices [85] for
environmental decontamination. Typically, hospital pa-
tients colonized with other multidrug-resistant organisms
are isolated to prevent transmission, but this appears to be
of limited value for asymptomatic C. difficile colonization.
In an epidemiological model, Lanzas and colleagues dem-
onstrated that transmission of C. difficile within a ward
cannot be sustained unless new C. difficile colonized pa-
tients are introduced [86]. Therefore, the admission of
asymptomatic C. difficile colonized patients plays an im-
portant role in sustaining C. difficile transmission within a
ward [87]. A recent study, has demonstrated that nearly
half of the C. difficile cases were genetically distinct from
all previous cases, which suggests genetically diverse
sources of infection [88]. Furthermore, Yakob and
colleagues demonstrated, using a stochastic mathematical
model, that screening for asymptomatic C. difficile
colonization to segregate colonized patients from non-
colonized patients had little impact on infection transmis-
sion because patients still in a latent period (exposed but
not yet colonized) would not be detected [89].
Risk factors for asymptomatic C. difficile colonization and
progression to active disease
Among inpatients with positive stool samples for C. diffi-
cile, McFarland and colleagues found that 52/83 (63 %) of
the patients were asymptomatic and 31/83 (37 %) devel-
oped symptoms of CDI [10]. Currently, the time required
to progress from asymptomatic C. difficile colonization to
active CDI is unknown; however, epidemiological studies
have identified risk factors associated with progression to
disease. It is not surprising to find common risk factors
for asymptomatic C. difficile colonization and disease
because colonization with C. difficile is a necessary pre-
requisite of disease. The most significant epidemiological
study to date to investigate risk factors for healthcare-as-
sociated asymptomatic C. difficile colonization identi-
fied that hospitalization within the last 12 months,
exposure to corticosteroids, history of CDI and pres-
ence of antibody against toxin B were significantly as-
sociated with healthcare-associated asymptomatic C.
difficile colonization [90]. Similar findings were described
by Loo and colleagues in 2011, they identified chemother-
apy, recent hospitalization, use of proton-pump inhibitors
or histamine H2 antagonists, and presence of antibodies
against toxin B were associated with healthcare-associated
asymptomatic C. difficile colonization [13]. The study also
found that antibiotic exposure (within 8 weeks of
hospitalization) was as a risk factor for healthcare-
associated CDI (OR 5.25, 95 % CI 2.15–12.82) but not for
healthcare-associated asymptomatic C. difficile colonization
(OR 1.04, 95 % CI 0.61–1.78). The apparent discrepancy
between the results may indicate that disruption of the
intrinsic intestinal microbiota due to antibiotic expos-
ure is not a key feature for C. difficile colonization as it
is for progression to disease. More recently, an investi-
gation conducted in a tertiary care facility identified
recent hospitalization, chronic dialysis, and corticosteroid
use as independent risk factors for toxigenic asymptomatic
C. difficile colonization on admission [91]. The eligible
patients’ first stool samples after admission were tested
for toxigenic C. difficile by real-time PCR assay. While
the study had limited generalizability, because the sub-
jects who participated in the study were predominantly
older (mean age 64 years), and due to the low propor-
tion of enrolled subjects who provided samples (22 %),
results were consistent with a previous study that
reported renal disease, prior hospital admission, and
prior CDI as risk factors for culture positivity on
admission [73].
There are limited data about risk factors for asymptom-
atic C. difficile colonization among healthy populations.
McNamara and colleagues investigated environmental fac-
tors associated with an increased risk of asymptomatic C.
difficile colonization in a cohort of healthy farm workers.
They found that reported weekly exposure to lake or pond
swimming was associated with asymptomatic C. difficile
colonization [29]; although, no biological plausible expla-
nations were given for this finding by the authors. A num-
ber of factors act in concert before asymptomatic C.
difficile colonization progresses to active disease. These
factors can be categorized as host mediated or pathogen
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related. A diagrammatic representation of the mechanism
of asymptomatic C. difficile colonization and progression
to disease with risk factors is shown in Fig. 1.
Host-mediated factors
The most significant factor that leads to CDI is the disrup-
tion of intrinsic colonization resistance. This is a feature of
the human intestine whereby indigenous microbiota, and
the presence of compounds that inhibit bacterial germin-
ation and proliferation protect individuals against diseases
caused by pathogenic organisms [54]. Factors that disrupt
the intestinal microbiota thereby allowing C. difficile to
flourish include treatment with antibiotics, proton-pump
inhibitors, and chemotherapy agents in addition to physical
effects of abdominal surgery and nasogastric tubes [13, 92].
Other host factors associated with an increased risk of
CDI include advanced age, multiple comorbidities, sup-
pressed immune system, inflammatory bowel disease
and dense intestinal co-colonization with enterococci
[27, 31, 69, 93–95]. It is worth pointing out that the ob-
served association between advanced age and multiple
comorbidities infection, and the increased risk of CDI,
may be confounded by medication exposure given that
polypharmacy is common among these groups of patients.
There is substantial evidence that asymptomatic C. dif-
ficile colonization has a protective effect against progres-
sion to disease through an immune-mediated response.
In a prospective study of hospital patients showed that
at the time of colonization, IgG levels were higher in
asymptomatic C. difficile colonized patients compared to
patients who subsequently developed diarrhea [18]. The
same authors demonstrated that patients with a single
episode of diarrhea had increased IgM levels against
toxins A, B and non-toxin antigens compared to patients
with recurrent disease, indicating that the presence of
these antibodies conferred a protective effect [96]. Many
healthy children and approximately 60 % of adults have
detectable serum IgG and IgA antibodies to C. difficile
toxins A and B, even when the organism is not detected
[97, 98]. If antibodies are stimulated during infancy and
through further exposure to C. difficile from the envir-
onment [99], it would suggest that protection against
CDI is a dynamic host-mediated characteristic [18, 100].
The control of toxin-induced intestinal inflammation by
Fig. 1 Diagrammatic representation of asymptomatic C. difficile colonization and progression to symptomatic C. difficile infection (CDI). Following
exposure to C. difficile spores, an individual may transiently or persistently harbor the organism without expressing typical CDI symptoms. In other
situations ingestion of C. difficile spores or vegetative cells may lead directly to symptomatic CDI. Some individuals with asymptomatic C. difficile
colonization may progress to symptomatic CDI, however a number of host and pathogen related factors can limit the progression of the disease
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up-regulation of A2B adenosine receptors in the intes-
tinal epithelium can also reduce the progression of ag-
gressive symptoms of disease [101]. In this study, an A2B
adenosine receptor antagonist did not reduce fecal toxin
levels in animal models but conferred protection against
progression of disease.
Pathogen factors
Colonization with non-toxigenic strains of C. difficile can
offer protection against infection, suggesting a possible
colonization resistance role through competition for nutri-
ents or access to mucosal epithelial cells [55, 102]. Com-
petition between clostridial strains may reduce the
proliferation of pathogenic strains and the onset of disease
symptoms [103]. Initial speculation was that toxigenic C.
difficile strains may be in the minority among asymptom-
atic C. difficile colonized patients [104]; however, it has
since been shown that the majority of strains are toxigenic.
Discussion and conclusion
Despite technological advances in C. difficile microbiol-
ogy and epidemiology (e.g. genotyping), asymptomatic
C. difficile colonization remains as a complex and chal-
lenging health problem as its epidemiological features
vary considerably between study groups and settings.
Several gaps in the current knowledge were identified in
this review that should guide future research studies:
1. There is no consistent definition for asymptomatic
C. difficile colonization; a standard definition across
studies is urgently needed.
2. The time between acquisition of C. difficile and
symptomatic disease is unknown but has been
estimated to be between 1 and 2 weeks [8, 13, 105].
It has also been suggested that progression to
disease happens within this short time after
acquisition or does not occur at all [73].
3. Asymptomatic C. difficile colonized patients serve as a
potential infection reservoir of horizontal transmission
of C. difficile in a range of healthcare settings and the
strain types isolated from patients with asymptomatic
C. difficile colonization are predominantly toxigenic
[9, 27, 30, 32, 40, 66, 70, 73, 91, 106]. However,
whether the clinical outcomes differ in asymptomatic
patients colonized with toxigenic C. difficile compared
to non-toxigenic strains it is currently unknown; thus,
we suggest that patients with diarrheal symptoms
with non-toxigenic strains of C. difficile should be
considered colonized unless there is definitive
evidence of disease.
4. Estimates of asymptomatic colonization may be
underestimated as stool culture is not practical in a
clinical setting; however, this constitutes important
future epidemiological study.
The current SHEA guidelines for CDI recommend that
active screening for asymptomatic C. difficile colonization
is not performed for infection control purposes [19].
Polage and colleagues retrospectively reviewed 6121 re-
cords of toxin negative patients and revealed that only one
(0.02 %) had a laboratory confirmed complication of CDI.
We emphasize that this recommendation for asymptom-
atic C. difficile colonization is still valid for the following
important reasons: first, there are limited options to manage
asymptomatic C. difficile colonized patients - they should
not be treated because antimicrobial therapy does not
eradicate spores [19, 72]; moreover treatment may render
patients more susceptible to symptomatic CDI [107]; and
second, asymptomatic C. difficile colonization might
protect individuals from progressing to active diseases [8].
Given the transmission potential of asymptomatic C.
difficile colonized patients, the increased prevalence
among certain clinical groups, limited management op-
tions, and the limited utility of screening, we suggest a
more pragmatic approach. Intensive infection control
practices, normally reserved for diseased patients, should
be targeted at individuals or clinical areas with higher
risk of asymptomatic C. difficile colonization. For ex-
ample, patient or unit-level risk assessments could target
enhanced environmental cleaning and use of gloves for
patient contact to limit the transmission of C. difficile
from asymptomatic C. difficile colonized patients [108].
Empirical research should be conducted into the impact of
targeted, risk-based, intensive infection control programs
before changes to the current SHEA guidelines for asymp-
tomatic C. difficile colonized patients are considered.
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